TMO · CIK 97745
What Thermo Fisher Scientific Inc. told the SEC could break it.
Thermo Fisher's disclosures center on the supply-chain exposures of a global life-sciences manufacturer. Many of its employees, contract manufacturers, suppliers and facilities sit outside the U.S., leaving results exposed to U.S. and foreign tariffs (and countermeasures) and to interruptions in the transportation flows for raw materials and finished goods — tariffs already pressured its Analytical Instruments margin in 2025. It is also concentrated at both ends of its supply chain: it relies on some sole- or limited-source suppliers for certain materials and components, and, in its CDMO role, it is itself the sole manufacturer of a number of pharmaceuticals for many customers — so a negative regulatory event at its facilities could impair those customers' ability to supply their own and expose it to contractual and product-liability claims.
3 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- tariffs (US and foreign) and transportation-flow interruptions; offshore manufacturing/supplier basemedium
Many of Thermo Fisher's employees, contract manufacturers, suppliers, outsourcing activities and manufacturing facilities are outside the U.S., exposing results to U.S. and foreign tariffs (and countermeasures) and interruptions to transportation flows for raw materials and finished goods; tariffs hurt Analytical Instruments segment margin in 2025.
“tariffs imposed by the U.S. on goods from other countries and tariffs imposed by other countries, on certain U.S. goods (including volatility resulting from the imposition of (and changing policies around) tariffs and related countermeasures); interruption to transportation flows for delivery of raw materials or parts to us and finished goods to our customers;”
- sole-manufacturer of pharmaceuticals for many customers — regulatory-event exposuremedium
Thermo Fisher is the sole manufacturer of a number of pharmaceuticals for many of its (CDMO) customers; a negative regulatory event at its facilities could impair those customers' ability to supply their own customers and expose Thermo Fisher to contractual and product-liability claims.
“We are the sole manufacturer of a number of pharmaceuticals for many of our customers and a negative regulatory event could impact our customers' ability to provide products to their customers.”
SEC filing →As of 2026
Sole-source dependency
- sole/limited-source suppliers for certain materials and componentsmedium
While no single supplier is material, some Thermo Fisher businesses purchase certain materials/components from sole or limited-source suppliers (for quality, regulatory, cost or unique-design reasons), and reliance on those sources could cause production interruptions, delays and inefficiencies.
“Some of our businesses purchase certain materials from sole or limited source suppliers for reasons of quality assurance, regulatory requirements, cost effectiveness, availa”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings — including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
Harmony Biosciences Holdings, Inc.
“we rely on Interor S.A., Corden Pharma Chenôve SAS and Patheon UK Limited to provide intermediate supply ingredients, API and finished products, respectively.”
Cited →“These sole source suppliers include Thermo Fisher Scientific, Inc., or Thermo Fisher, which supplies us with instruments, laboratory reagents and consumables”
Cited →“EXPAREL is currently manufactured at our facilities in San Diego, California; both EXPAREL and ZILRETTA are currently manufactured at the Thermo Fisher facility in Swindon, U.K.”
Cited →“The agreements provide for Patheon to manufacture and supply ARIKAYCE for our anticipated long-term commercial needs. Under these agreements, we are required to deliver to Patheon the required raw materials, including active pharmaceutical ingredients, and certain fixed assets needed to manufacture ARIKAYCE.”
Cited →Supernus Pharmaceuticals, Inc.
“We have agreements with CMOs headquartered in North America, including: Patheon Pharmaceuticals, Inc. (a subsidiary of Thermo Fisher Scientific Inc.), Packaging Coordinators, Inc., Aphena Pharma Solutions, and Catalent Pharma Solutions, Europe, and Asia for the manufacturing and packaging of some of our commercial products”
Cited →Ultragenyx Pharmaceutical Inc.
“The pharmaceutical-grade drug substance for Dojolvi is manufactured by IOI Oleo GmbH, or IOI Oleo, in Germany under an exclusive worldwide supply agreement. The drug product is manufactured by Patheon Pharma Services by ThermoFisher Scientific, our CDMO partner.”
Cited →“Under the manufacturing agreement with Patheon, we have agreed to purchase from Patheon a specified percentage of our commercial requirements”
Cited →“We procure certain reagents, equipment, chips/cards and other materials used to perform our tests from sole suppliers such as ThermoFisher Scientific, Inc., Promega and Qiagen, Inc. Some of these items are unique to these suppliers and vendors.”
Cited →
Its suppliers
“We sell our products directly to customers who are primarily located in North America, Europe and China, as well as through a distribution agreement with Thermo Fisher Scientific.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch